In addition to new sites, which will be announced later, the company will expand its existing manufacturing facilities in Beijing, Qingdao, Taizhou, and Wuxi.
It will take the company years to recoup its investment in the large-scale mammalian drug substance facility, acquired in 2024 from Roche for $1.2 billion.
